granted
on 14 Feb 2024
Last Applicant/ Owned by
107, Ihyeon-ro 30beon-gil, Giheung-gu,
Yongin-si, Gyeonggi-do
KR
16924
Serial Number
90160114 filed on 04th Sep 2020
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCRead More
Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), for preventing primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), and for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP); all the foregoing for patient treatment by injection or in liquid form by health professional
No 90160114
No Service/Collective Mark
No 5734-0284TM
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
03rd Apr 2024 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
15th Feb 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
14th Feb 2024 | SOU TEAS EXTENSION RECEIVED |
14th Feb 2024 | SOU EXTENSION 4 FILED |
14th Feb 2024 | SOU EXTENSION 4 GRANTED |
30th Aug 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
28th Aug 2023 | SOU TEAS EXTENSION RECEIVED |
28th Aug 2023 | SOU EXTENSION 3 FILED |
28th Aug 2023 | SOU EXTENSION 3 GRANTED |
24th Feb 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |